GlassScriptPhysician profile
Lindsay M Huffman
NPI 1427536911
$4,790.13
in general payments reported to CMS, 2019-2025
25 companies · $3,491 in 2025
The $3,491 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,300 · 2025: $3,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126 · Consulting Fee: $525 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,126.14 |
| Consulting Fee | $525.00 |
| Education | $138.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,263.94 | 2024-2025 | Krystexxa, Tavneos, Otezla |
| Alexion Pharmaceuticals, INC. | $610.73 | 2024-2025 | Strensiq, Ultomiris |
| Abbvie INC. | $540.71 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $499.27 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $329.66 | 2024-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $264.87 | 2024-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $207.71 | 2024-2025 | Taltz, Zepbound |
| Sobi, INC | $139.18 | 2024-2025 | |
| Janssen Biotech, INC. | $131.65 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals LP | $96.84 | 2024-2025 | Saphnelo |
| Organon LLC | $85.15 | 2024-2025 | Hadlima |
| Genentech USA, INC. | $84.86 | 2024-2025 | Actemra, Gazyva |
| Sandoz INC. | $73.38 | 2024-2025 | Hyrimoz, Jubbonti |
| Radius Health, INC. | $70.89 | 2025 | Tymlos |
| Mallinckrodt Hospital Products INC. | $59.99 | 2025 | Acthar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.93 | 2025 | Hyqvia, Cuvitru |
| Glaxosmithkline, LLC. | $55.24 | 2025 | Benlysta |
| Fresenius Kabi USA, LLC | $44.30 | 2025 | |
| Hospira, INC. | $39.65 | 2025 | |
| Aurinia Pharma U.S., INC. | $33.35 | 2025 | Lupkynis |
| United Therapeutics Corporation | $26.60 | 2024 | Tyvaso |
| Pfizer INC. | $21.62 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $19.26 | 2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.19 | 2025 | Spevigo |
| Genzyme Corporation | $13.16 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.